The weight-loss drug wars just went international. Eli Lilly won UK approval for its oral GLP-1 pill Foundayo (orforglipron) on Monday, its first green light outside the United States, setting up a direct clash with Novo Nordisk’s Wegovy pill in one of the world’s most closely watched pharmaceutical markets. It’s only the second oral weight-loss pill approved in Europe, arriving just two months after Novo’s version launched there.
The competitive dynamics are worth tracking closely. Foundayo launched in the U.S. back in April and generated $98 million in second-quarter sales — a respectable start, but notably slower than Wegovy’s pill uptake, according to Lilly CEO David Ricks, who told CNBC in April the drug simply needs more time to establish itself with doctors and patients. Lilly is leaning on a key differentiator: unlike Wegovy, which requires patients to take it first thing in the morning with water and no food for 30 minutes, Foundayo is a small-molecule drug that can be taken without those food restrictions. Novo, meanwhile, is showing strong momentum of its own — CEO Mike Doustdar said roughly 300,000 UK patients started on the Wegovy pill within its first three weeks of availability, and he’s betting the oral pill market could eventually rival injectables in size. Foundayo will still need a cost-effectiveness review from the UK’s NICE body before it’s available through the National Health Service, a hurdle that could delay broader uptake.
For investors in either name, this is a market-share story more than a binary win-or-lose event. Both companies argue oral pills are expanding the overall weight-loss market rather than just cannibalizing injectable sales, which is bullish for total addressable market size across the sector. Lilly shareholders should watch U.S. prescription trends for Foundayo as the best leading indicator of whether its ease-of-use pitch is resonating, while Novo holders should track UK reimbursement decisions as a proxy for how fast reimbursement-dependent, international markets adopt these pills. Either way, the GLP-1 pill category looks like it has room to grow for both players.
